small molecule

ASACOL

MESALAMINE

Loss of exclusivityloss of exclusivity
CompanyALLERGAN PHARMACEUTICALS INTERNATIONAL LTD

Drug detail

Brand nameASACOL
Active ingredientMESALAMINE
Strength400MG
Dosage formTABLET, DELAYED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalJanuary 1992
Marketing statusDISCN

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

ASACOL patent cliff — loss of exclusivity — | CliffBio